Privatizing biomedical research - a 'third way'

被引：13

作者：

Bouchard, Ron A. ^{[1
]}

Lemmens, Trudo ^{[2
]}

机构：

[1] Univ Alberta, Fac Law & Med & Dent, Edmonton, AB T6G 2H5, Canada

[2] Univ Toronto, Fac Law & Med, Toronto, ON M5S 2C5, Canada

来源：

NATURE BIOTECHNOLOGY | 2008年 / 26卷 / 01期

关键词：

D O I：

10.1038/nbt0108-31

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The allocation of risks and benefits of publicly sponsored biomedical research is becoming increasingly skewed toward for-profit entities and against the public interest. A legitimate solution to this imbalance would be to levy compulsory government royalty fees on commercial products made possible by public efforts.

引用

页码：31 / 36

页数：6

共 55 条

[51]

WALSH JP, 2002, PATENTS KNOWLEDGE BA, P285

[52]

Walzer M., 1983, SPHERES JUSTICE

[53] Emergent patterns in the regulation of pharmaceuticals: Institutions and interests in the United States, Canada, Britain, and France [J].

Wiktorowicz, ME .

JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2003, 28 (04) :615-658

[54] Changes in innovation ecology [J].

Wulf, William A. .

SCIENCE, 2007, 316 (5829) :1253-1253

[55] The NIH roadmap [J].

Zerhouni, E .

SCIENCE, 2003, 302 (5642) :63-+

← 1 2 3 4 5 6 →